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Factors Modulating the Secretion of
Thyrotropin and other Hormones of the
Thyroid Axis
by George A. Hedge,* Ken C. Wright,t and Allan Judd*
The first portion of this paper is devoted to an overview of the normal function of the
hypothalamo-pituitary-thyroid axis. This section emphasizes areas of current research interest
and it identifies several sites and mechanisms that are potentially important interfaces with
toxins or toxic mechanisms. We then describe an in vitro technique for the continuous
superfusion of enzymatically dispersed pituitary cells; this approach is particularly valuable in
studying the dynamics of the TSH responses to the factors known (or suspected) to regulate
TSH secretion in vivo. Using this technique, we have found that 10M prostaglandin (PG)I2
stimulates TSH secretion without altering the response to TRH (10'M), and that this
stimulation is not due to its rapid conversion to 6-keto PGF1,,. In contrast PGs of the E series
(PGE1 and PGE2, 10M) increase responsiveness to TRH but have no effect alone. We found no
effects of any of the other prostanoids tested (PGs A2, B2, Fla, F2a, thromboxanes A2 and B2, and
the endoperoxide analog, U-44069. Somatostain (109M) inhibits TRH-induced TSH secretion,
but does not alter the responsiveness to PGI2. These findings suggest that somatostatin blocks
TSH secretion at a point that is functionally prior to the involvement of the PGs, and perhaps
does so by blocking synthesis or limiting availability of selected PGs.

I have chosen a title for this paper that reflects
my perception of the twofold mission I have been
given. First, I will use this initial paper of the session
as a "stage setter" in that I will review the basic
physiology of the thyroid axis and how its components interact under normal conditions. For the
benefit of those who are not actively involved in
research in this area, I will try to update the topic
by pointing out areas of particular current research
interest. My second goal is to emphasize, and to
document by reference or presentation of data,
certain aspects of the thyroid axis that are not
likely to be covered by subsequent speakers. This
presentation will not be laden with data concerning
endocrine toxicity, but it is hoped that it will serve
to identify a number of critical points in this
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neuroendocrine axis at which one might predict
interactions with toxins or toxic mechanisms.

Overview of the Thyroid Axis
Figure 1 presents the various elements and
functional connections that comprise the neuroendocrine system of interest. Each of the three
organs depicted (hypothalamus, anterior pituitary,
and thyroid gland) may be considered as a target
for an endogenous hormone or neurotransmitter.
Of course, any of these could also be a target for
some toxic compound. From the systems control
standpoint, this axis operates as a classical negative
feedback system with the serum concentration of
thyroid hormone being the controlled variable. The
immediate controller is thyroid stimulating hormone (TSH) which is secreted by the anterior
pituitary. This secretory process, in turn, can be
stimulated or inhibited by hypothalamic factors,
and can also be inhibited by the negative feedback
effects of thyroid hormones.
I have just referred to the secretions of the
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FIGURE 1. Schematic overview of the hypothalamopituitary
thyroid axis.

thyroid gland simply as thyroid hormones. However, I would now like to recognize some of the
individual members of this class of hormones, and
briefly describe our current state of knowledge
about these substances. Thyroxine (T4) is a tetraiodothyronine secreted in relatively large quantities by the thyroid, and is, of course the classical
thyroid hormone. In contrast, the other two substances listed with T4 (T3 and reverse T3) are both
triiodothyronines that differ structurally only in
that the fourth iodine is missing from the outer ring
in the case of T3 (i.e., 3,5,3'-triiodothyronine),
58

whereas it is missing from the inner ring in the case
of reverse T3 (3,3',5'-triiodothyronine). In addition
to this structural similarity, these two triiodothyronines are also similar in that they are derived in
large part from peripheral (i.e., extrathyroidal)
deiodination of circulating T4 rather than from
direct secretion by the thyroid gland. Although
virtually all of the circulating T4 is secreted directly
by the thyroid only a fraction (estimates vary from
10 to 40%) of the circulating T3 is secreted directly
from the thyroid gland. Even less (if any) of the
circulating reverse T3 is secreted by the thyroid. In
spite of the similarities between these triiodothyronines (structure and source), the two differ
radically in one very important way-namely,
their biological activity. T3 is approximately four
times as active as T4 on a molar basis, whereas
reverse T3 is virtually inert under physiological
conditions. Thus, it is clear that the peripheral
deiodination of T4 is an important source of thyroid
hormones both qualitatively and quantitatively.
The qualitative importance is that this mechanism
can produce either the most, or the least, active
thyroid hormone. From the quantitative standpoint, the most potent thyroid hormone (T3) is
derived largely from this source.
Not surprisingly, this deiodinating mechanism
and the regulation of its activity has been the topic
of considerable research interest recently (1). Clinical endocrinologists have particularly been interested after finding numerous circumstances in which
one sees reciprocal changes in the serum concentrations of T3 and reverse T3. For example, starvation
or numerous severe illnesses result in an increase in
circulating levels of reverse T3 at the apparent
expense of T3, which falls concomitantly. The
enzymic processes which result in the monodeiodination of T4 at the inner or the outer ring are
known to occur in numerous tissues, primarily in
the liver and kidney. However, we are just beginning to recognize some of the mechanisms that
regulate these processes. I would like to point out
though, that as this story has developed there has
been considerable speculation that T4 might in fact
be only a prohormone (i.e., that it might have to be
deiodinated to T3 in order to be hormonally active).
Although this hypothesis has attracted considerable attention and has undoubtedly been of heuristic value, it seems clear now that T4 itself can
indeed act as a hormone at least regarding some of
its effects. In such cases, it may well be that the T4
is deiodinated within the target cells in the process
of exerting its effect. Nonetheless, it is the T4 that
has functioned in the classical sense of a hormone,
that is, it has transmitted the message from the
point of origin to the target tissue.
Environmental Health Perspectives

It is particularly germane to this symposium to
point out that the monodeiodination of T4 to either
T3 or reverse T3 may be viewed as a branch point
that has the potential to function as a very powerful
peripheral regulator of the thyroid state. Consequently, this is one rather obvious place for toxicologists to direct their energies in the study of the
toxicity of the thyroid axis.
Before proceeding upward in the system depicted
in Figure 1, I should point out the great likelihood
of the effects of toxins at another site in the
periphery, namely, at the interaction between the
thyroid hormones and their binding proteins in
serum. Normally, these honnones are predominantly
(i.e., greater than 99%) bound to these proteins. If,
as most believe, only the free fraction of these
hormones is active, then shifts in binding without
other compensation can result in changes in the
thyroid state. Many drugs are already known to
alter the protein binding of thyroid hormones, and
certainly any other foreign compound (or toxin)
should be considered in this light as well.
Although these events located "below" the thyroid in a functional sense are incredibly important
in the overall regulation of the thyroid axis, they do
not detract from the importance of factors that
alter secretion by the thyroid itself since this gland
provides not only a portion of the active hormone
pool, but it also provides all substrate for the
peripheral deiodination. Of course, under normal
physiological conditions, the rate of secretion by
the thyroid is primarily determined by the concentration of TSH to which it is exposed. In a moment,
I will return to the results of some recent experiments dealing with the factors that regulate TSH
secretion. Before that, and consistent with my
mission, I would like to point out that a number of
factors other than TSH can also alter thyroid
secretion. Recognizing that there may be overlap
within the list, and with the primary mechanism
(TSH), some factors worth mentioning are the
following: (1) immunoglobulins-in particular, the
immunoglobulin associated with Grave's disease
which stimulates all aspects of thyroid hormone
synthesis and secretion, probably via cyclic AMP;
(2) iodine; (3) drugs--numerous antithyroid drugs
act at various sites within the thyroid hormone
cascade; (4) diet-of primary concern are the iodine
mentioned above and the so-called "goitrogens"
found in some foodstuffs; (5) adrenergic nerves-at
least in animal studies, it seems clear that norepinephrine from never terminals within the thryroid
can activate thyroid hormone secretion; (6) hormones other than TSH-for example, estrogens
and glucocorticoids, which may exert their effects
via binding proteins and/or TSH; and (7) ageApril 1981

there are several interesting transients in thyroid
hormone levels during the pre- and neonatal period,
and other more gradual changes throughout life
into old age. In addition to these factors which we
might classify as extrathyroidal factors, we should
also consider intrathyroidal factors such as cyclic
nucleotides, prostaglandins, and polyamines. These
are actually suspected mediators of TSH action.
Unfortunately, the associated biochemistry and
physiology is still loaded with uncertainty in spite
of much current research activity (2). In any case,
any toxicity relating to the economy of these
ubiquitous substances might well be expected to
affect thyroid function.

Regulation of Thyrotropin
Secretion: Superfusion of
Enzymatically Dispersed Pituicytes
I would now like to turn to the regulation of the
secretion of the primary controller of thyroid function, i.e., TSH. This hormone is secreted by the
anterior pituitary, and is under the influence of
three humoral factors. The first of these is the
negative feedback inhibition by thyroid hormones
arriving via the systemic circulation (Fig. 1). In
addition, there are two hypothalamic hormones
that arrive via the hypothalamo-hypophyseal portal
vessels which can alter TSH secretion; thyrotropin
releasing hormone (TRH) stimulates TSH secretion, and somatostatin (SRIF) inhibits TSH secretion. I must emphasize the significance of this latter
vascular connection which arises in the region of
the medial basal hypothalamus as a capillary plexus, and terminates only a short distance away in the
sinusoids of the anterior pituitary. Experimentally,
it is often necessary to distinguish between a
pituitary and a suprapituitary site of action of some
substances. As you might imagine, this very closely
coupled series configuration often complicates such
experiments. In attempting to surmount this problem several years ago, we (3) and others (4)
addressed the anterior pituitary directly by a
stereotaxic approach, and still others (5) have used
a more demanding approach of placing a micropipet
into a single portal vessel. However, our recent
efforts in this regard have been concerned with an
in vitro system which we feel has a number of
advantages over the classical static incubation of
hemipituitaries.
We have established a system for the continuous
superfusion of enzymatically dispersed anterior
pituitary cells (Fig. 2). This system has some
elements in common with those described by Lowry
(6), Schrey et al. (7), and Mulder and Smelik (8). A
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FIGURE 2. Diagram of system for continuous superfusion of
enzymatically dispersed pituitary cells and collection of
effluent for hormone assay.

peristaltic pump draws mixed and gassed buffer
through a pair of chambers containing collagenasedispersed pituicytes supported on Sephadex. Each
column contains 6 to 10 million cells which can be
exposed to various substances using valves that
divert the flow just upstream from the cell columns.
The effluent is collected for radioimmunoassay of
TSH using a fraction collector set at a frequency
appropriate for the given experiment. After a
transient period of relatively high TSH release, a
stable baseline is achieved and the cells are quite
responsive to exogenous TRH (Fig. 3). We normally allow 2 hr for stabilization, and then we continue
to use the cells for approximately 6 hr, although we
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FIGURE 4. Comparison of response dynamics of dispersed cells
and pituitary fragments. In the latter case, each anterior
pituitary was cut into 10 pieces.

ple, if one is interested in studying the dynamics of
pituitary secretion (as we are), then the dispersed
cells constitute the preparation of choice, as shown

in Figure 4. From these responses to 2-min pulses
of TRH, it is clear that the user of dispersed cells
pays a bit of a price regarding the magnitude of the
response, but he gains considerably regarding stability of response.
Of course, during a typical 6-hr experiment, we
want to stimulate the cells repeatedly under various experimental conditions. For this reason, it is
important to know that the responsiveness of these
cells is constant under constant conditions. We
have provided this assurance by demonstrating
consistent responses to a train of constant,
nonmaximal TRH stimuli with interstimulus intervals varying between 20 and 70 min (unpublished
observations). Finally, in describing the basic characteristics of this system, I should mention the
effect of the second hypothalamic hormone listed on
Figure 1, namely, somatostatin. As will be
documented on a later slide, this peptide does not
affect basal TSH secretion, but it does inhibit
TRH-induced TSH secretion. It is interesting to
note that even maximal doses of somatostatin fail to
completely suppress TRH-induced TSH secretion.
Environmental Health Perspectives

These findings are consistent with the results from
other laboratories (9, 10).
Thus the effects of somatostatin and TRH that I
have described agree with the depiction in Figure
1. However, this does not address the issue of
physiological roles for these two peptides in regulating TSH secretion. Perhaps the best evidence to
support such roles comes from passive immunization studies from other laboratories. For example,
it has been shown that the administration of TRH
antiserum to conscious rats blocks the cold-induced
TSH response, suggesting that endogenous TRH is
involved in mediating this response (11). Similarly,
the administration of somatostatin antiserum enhances both basal and TRH-stimulated TSH secretion, providing some evidence for a physiological
role for this peptide as well (12).

Effects of Prostaglandins on
Thyrotropin Secretion
Our primary interest in somatostatin and TRH in
this superfusion system is in their usefulness as
tools to help us define more clearly the roles of
other substances thought to be involved in regulating TSH secretion. Recently, we have been particularly interested in using this approach to follow-up
our earlier in vivo studies of the roles for
prostaglandins (PGs) in regulating pituitary secretion (13). This earlier work concentrated on the
so-called stable PGs typified by those of the E
series and the F series. Since that time, numerous
new members of the prostanoid family have been
recognized, such as the endoperoxide intermediates
(PGG2 and PGH2), prostacyclin (PGI2), and the
thromboxanes (14). Thus, we have recently used
our in vitro system to investigate some of these
prostanoids in relation to pituitary secretion in
general; I will present some of our findings regarding TSH in particular.
One of the primary findings is that prostacyclin
can stimulate TSH release on its own, but it leaves
the responsiveness to TRH relatively unaffected.
This can be seen in each of the three panels of
Figure 5, the left of which makes use of our
standard superfusion medium containing bovine
serum albumin (BSA). The other two experiments
were performed at a time at which we suspected
that protein in the medium was inhibiting the effect
of the prostacyclin. Since this was true only if the
prostacyclin solutions were prepared well in advance of the experiment, we soon circumvented
this problem by using only freshly prepared
prostacyclin solutions. Thus, the patterns of responses seen in the three panels of Figure 5 are
April 1981
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FIGURE 5. Stimulation of TSH release by prostacyclin (PGI2) in
the presence of three different types of media. Our standard
medium is Hams F10 with bovine serum albumin (5 mg/ml,
BSA, left panel). The medium used for the center panel was
F10 without BSA, whereas the one on the right was F10
made isosmotic with dextran rather than BSA.

identical. However, it is also clear that both basal
and TRH-induced TSH secretion is greatly
suppressed without the normal complement of
protein in the medium. Apparently this is not due
to osmotic imbalance since the restoration of normal osmolality by dextran (right hand panel) does
not restore normal basal or TRH-induced TSH
secretion. It is interesting, but also unexplained,
that the effect of prostacyclin is greater in the
dextran-containing medium than in the standard
BSA-containing medium. Since it is known that
prostacyclin is rapidly converted to the metabolite
6-keto PGF1,,,, we were concerned that it might in
fact be this metabolite that stimulates TSH secretion rather than the prostacyclin itself. However,
we have shown that this is not the case since the
same dose of 6-keto PGFia is completely without
effect on TSH secretion (Wright and Hedge,
unpublished observations).
In contrast to the effect of prostacyclin, PGE2
accentuates the responsiveness to TRH, but does
not affect basal TSH secretion (Fig. 6). The magnitude of this effect is rather small, but it is seen
repeatedly and is consistent with our previous in
vivo studies (13), and with the reports of others
using static in vitro systems (15, 16). Although not
shown here, the effect of PGE1 is virtually identical
to the effect shown in Figure 6, both qualitatively
and quantitatively. The effects described for
prostacyclin and PGs of the E series are quite
specific in that a number of other prostanoids tested
in exactly the same way have been found to be
totally ineffective. Figure 7 shows typical results
from experiments with PGD2 and the stable
endoperoxide analog U-44069. Negative results
identical to these were also obtained upon testing
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FIGURE 6. Accentuation of responsiveness to TRH by PGE2
with normal responses of the same column shown before and
after the PGE2 treatment.

PGs A2, B2, Fla and F2a, and thromboxanes A2 and
B2.
The final point to be made regarding exogenous
PGs concerns the effects of somatostatin. We have
seen the inhibition of TRH-induced TSH secretion
by somatostatin, and we have also seen the interactions between TRH and PGs. Figure 8 presents an
example of interaction among all three substances.
First, I should point out that the dose of somatostatin
used in this experiment exerts maximal inhibition
(to approximately 35% of control) of the response to
a rather high dose (10-7M) of TRH. This dose of
I TRH (168M)
601 EJ U-44069 (10-5M)
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FIGURE 7. Failure of endoperoxide analog (U-44069) or PGD2
to affect either basal or TRH-induced TSH secretion.
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somatostatin inhibits the response to TRH (at
1leM) as expected. However, it does not alter the
effect of the prostacyclin alone. This finding, and
other similar ones with PGs of the E series, suggest
to us that somatostatin inhibits TRH-induced TSH
secretion at some point prior to the involvement of
the PGs. One possible mechanism worth considering, and worth investigating, is that somatostatin
might inhibit TSH secretion by inhibiting PG formation. The PGs of the E series would seem to be
particularly likely candidates to be involved in such
a mechanism since they enhance responsiveness to
TRH while leaving basal TSH secretion unaffected,
and somatostatin inhibits TRH stimulated TSH
secretion and leaves basal secretion unaffected.
Although not presented in detail in this paper, we
already know that the inhibition of TRH-induced
TSH secretion by somatostatin can be completely
reversed by replacement with exogenous PGE1 or
PGE2, even though these prostanoids cannot stimulate TSH secretion on their own (Fig. 8).
All of the data that I have presented thus far
have been concerned with the effects of exogenous
prostanoids on TSH secretion. The logical next
question is to ask whether or not the endogenous
pituitary PGs are actually involved in the normal
regulation of TSH secretion. In extending the
present studies, we have begun to examine this
issue using our superfusion system. In doing so, we
have made use of several pharmacological tools
commonly used in PG studies. In particular, we
have used indomethacin to inhibit PG synthesis and
found that that this greatly reduces the amount of
TSH secreted in response to TRH. The fact that
this inhibition can be reversed by reintroducing
exogenous PGs suggests that the effect is indeed
due to inhibition of PG synthesis rather than some
Environmental Health Perspectives

nonspecific effect of the drug. Conversely, we have
enhanced the responsiveness to TRH by superfusing
these cells with excess PG precursor (i.e., arachidonic
acid). Although these studies are not yet complete,
they certainly suggest that endogenous PGs are
involved in regulating TSH secretion as one might
predict from the findings that I have presented
from our work with exogenous PGs.
Studies in the author's laboratory were supported in part by
USPHS Grants AM21348 and AM07312.
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